Detection of the virulent neurotropic fungus Cladophialophora bantiana in clinical samples, primarily CNS tissue, increased four-fold in the period from 2023 to 2025.
News|Articles|September 2, 2026
Paxlovid Shows No Benefit for Long COVID
Fact checked by: Justin Mancini
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
Advertisement
Extended-duration nirmatrelvir and ritonavir (Paxlovid; Pfizer) did not reduce long COVID symptoms compared with placebo in the RECOVER-VITAL viral persistence trial. Results were published in The Lancet Infectious Diseases and funded by the National Institutes of Health (NIH) as part of the Researching COVID to Enhance Recovery Initiative.1
Investigators pointed to methodological lessons from the trial beyond the negative primary result.
"This study contributes important findings to the science of studying long COVID and viral persistence," Lindsey Baden, MD, of Mass General Brigham and co–principal investigator of the trial, said in a statement. "We learned how to better characterize and measure the symptoms our patients with long COVID are suffering from. Unfortunately, treating viral persistence with this antiviral medication did not show evidence of clinical benefit."2
The symptom-group stratification approach used in RECOVER-VITAL offers a model for characterizing and measuring heterogeneous long COVID presentations in future studies.
What the Study Data Showed
Investigators tested 3 treatment durations across 959 adults with long COVID enrolled at 69 sites nationwide. Investigators randomly assigned participants across 3 arms: 25 days of nirmatrelvir/ritonavir, 15 days of nirmatrelvir/ritonavir followed by 10 days of ritonavir plus placebo nirmatrelvir, or 25 days of ritonavir plus placebo nirmatrelvir. Before random assignment, each participant was assigned to 1 of 3 symptom groups based on self-reported long COVID concerns: cognitive dysfunction, autonomic dysfunction, or exercise intolerance and postexertional malaise. Approximately 320 participants fell into each symptom group, though treatment-arm assignment operated independently of symptom classification, meaning participants within a single symptom group could land in any of the 3 dosing arms.
Over 6 months, participants completed periodic surveys rating symptom severity alongside in-clinic visits and laboratory testing. None of the 3 symptom groups showed meaningful improvement with extended nirmatrelvir/ritonavir dosing relative to placebo. The uniform lack of benefit across cognitive, autonomic, and exercise-related symptom clusters suggests viral persistence, if present, may not drive long COVID symptoms in the way investigators hypothesized. Notably, the longer 25-day course did not raise new safety concerns compared with the standard regimen.
About the RECOVER trial
The trial is 1 of 8 RECOVER clinical trials evaluating interventions for symptoms affecting quality of life for patients with long COVID. Enrollment ran from July 2023 through early 2025, and investigators grouped participants by predominant symptom domain before random assignment. This design allowed comparisons across cognitive, autonomic, and exercise-related symptom clusters within a single trial framework.
The RECOVER Initiative is an NIH-funded, patient-centered research network established to understand, diagnose, prevent, and treat long COVID, a chronic condition persisting for at least 3 months after SARS-CoV-2 infection. Along with Mass General Brigham’s Baden serving as co–principal investigator for RECOVER-VITAL, a group of patient, caregiver, and community representatives helped design the trial protocol and advised on participant experience throughout enrollment.
Site-level details for all 69 participating locations are available through ClinicalTrials.gov, and additional information on the broader RECOVER trial portfolio is available at trials.recoverCOVID.org.
References
1. Baden LR, Shah NS, Liu STH, et al; RECOVER-VITAL Clinical Trial Group. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. Published online August 31, 2026. doi:10.1016/S1473-3099(26)00406-8
2. RECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for long COVID. News release. Brigham and Women's Hospital. August 31, 2026. Accessed September 2, 2026.
https://www.eurekalert.org/news-releases/1142039?
Advertisement
Related to this article
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
As of October 15, CDC reports 9235 confirmed cases and 4444 deaths in the Bundibugyo virus Ebola outbreak in the DRC, now the second-largest on record.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
Serial bloodstream isolates from two critically ill London patients showed heteroresistance, CRZ1 escape mutations, and drug-induced polyploidy despite wild-type FKS1 and susceptible MICs.
Advertisement
Advertisement